Author:
Sridhar Srikala S.,Canil Christina M.,Chi Kim N.,Hotte Sebastien J.,Ernst Scott,Wang Lisa,Chen Eric X.,Juhasz Agnes,Yen Yun,Murray Peter,Zwiebel James A.,Moore Malcolm J.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference23 articles.
1. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI (2008) Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14:2763–2767
2. Bjorklund S, Skog S, Tribukait B, Thelander L (1990) S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry 29:5452–5458
3. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461–3467
4. Buch-Hansen TZ, Bentzen L, Hansen S, Hoeyer M, Jensen NV, Saxe C, Sengeloev L (2009) Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. Cancer Chemother Pharmacol
5. Cricca A, Marino A, Valenti D, Melotti B, Amaducci E, Guardigli C, Lenzi M, Martorana G, Buli P, Martoni AA (2006) Gemcitabine plus mitoxantrone and prednisone in the palliative treatment of hormone-resistant prostate cancer (HRPC): a phase II study (GOAM 01.01 study). Anticancer Res 26:2301–2306
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献